# Evaluating Appetite and Eating Behaviors in Retatrutide Research with the EBAQ

Canonical source: https://retacompare.com/research/evaluating-appetite-and-eating-behaviors-in-retatrutide-research-with-the-ebaq

Clinical Trials · 2026-01-01


    The Eating Behavior and Appetite Questionnaire (EBAQ) enhances the assessment of appetite and eating behaviors in individuals with obesity, particularly in the context of retatrutide treatment. Developed through literature reviews and participant interviews, the EBAQ aims to provide a comprehensive tool for understanding how obesity treatments influence eating habits.

 What this source covers

This source details the development and content evaluation of the EBAQ, a new patient-reported outcome (PRO) measure specifically designed for individuals with obesity. The EBAQ was created based on insights from a targeted literature review, participant feedback from a phase 2 trial of retatrutide (NCT04881760), and clinician interviews. The questionnaire consists of 21 items organized into three domains that assess eight key concepts related to appetite and eating behaviors. Cognitive interviews conducted with adults with obesity confirmed the clarity and relevance of the questionnaire items, with participants reporting a positive overall impression.

 Why it matters for Retatrutide research

The EBAQ is particularly significant for retatrutide research as it addresses a gap in existing PRO measures that inadequately capture the nuances of appetite and eating behaviors in individuals undergoing obesity treatment. By providing a structured way to evaluate these factors, the EBAQ can facilitate a deeper understanding of how retatrutide and similar medications impact patient outcomes. This enhanced assessment may lead to more tailored treatment approaches and improved management strategies for obesity.

 Key findings or claims

The EBAQ was developed based on literature reviews and participant feedback from a phase 2 trial of retatrutide.

It consists of 21 items organized into three domains, focusing on eight relevant appetite and eating behavior concepts.

Cognitive interviews with 24 participants indicated that 96% found the response options clear and appropriate.

All participants reported understanding the instructions and recall period effectively.

The EBAQ is intended for use in clinical trials, clinical practice, and observational research.

 Context and prior work

This development aligns with ongoing research into GLP-1, GIP, and glucagon pathways, which are critical in the pharmacological management of obesity. Prior studies have established the importance of understanding appetite regulation and eating behaviors in the context of obesity treatment, particularly with medications like retatrutide that target these mechanisms. The EBAQ complements existing research by offering a validated tool to measure patient-reported outcomes in this domain.

 Practical takeaways for researchers

Researchers focusing on retatrutide and obesity management should consider incorporating the EBAQ into their studies to gain insights into how treatments affect patient behavior and perceptions. The questionnaire's structured approach can enhance data collection and analysis, leading to more informed conclusions about treatment efficacy. Furthermore, the EBAQ can serve as a valuable resource in clinical practice, aiding healthcare providers in understanding patient experiences and tailoring interventions.

 FAQ

 What is the purpose of the EBAQ?

The EBAQ is designed to comprehensively assess appetite and eating behaviors in individuals with obesity, particularly those undergoing treatment.

 How was the EBAQ developed?

The EBAQ was developed through literature reviews, interviews with trial participants, and consultations with obesity medicine specialists.

 Can the EBAQ be used in clinical practice?

Yes, the EBAQ can be utilized in clinical trials, clinical practice, and observational research to evaluate the impact of obesity treatments on appetite and eating behaviors.

 Source: PubMed · Adv Ther · published 2026-01-01.

## Sources

- PubMed · Adv Ther: https://pubmed.ncbi.nlm.nih.gov/41201783